JAKARTA – PT Prodia StemCell Indonesia (ProSTEM), sister company of PT Prodia Widyahusada Tbk (PRDA), officially inaugurates Advanced Cell Therapy-Production Laboratory (ACT-PLab) phase one today (11/12) in Kramat, not far from Prodia headquarter at Prodia Tower.

ProSTEM has been present in the last 10 years, initiated by Andi Wijaya, now serving as President Commissioner of ProSTEM. This facility is projected to be one of the biggest and most comprehensive stem cell development and processing facility in Asia.

This building is erected upon land 2,100-m2 land. “Investment for this building reaches over IDR 100 billion, until the second phase,” revealed Dr. Cynthia R. Sartika, Director of ProSTEM, during the press conference of the Inauguration of Advanced Cell Therapy-Production Laboratory (ACT-PLab).

Then, next year, Sartika announced ProSTEM’s plan to pick up ACT-PLab construction, phase two. “The area may only be a quarter of this building,” she added.

“I have benchmarked against Germany, South Korea. We are not behind, we are even better, particularly in procedures. However, technology-wise, they are still more advanced. That is what we must continue to learn,” said Sartika.

Sartika further admitted that the device and machine inside the lab, even supporting devices and materials, including alcohol, are imported. “Our investors are purely PT Prodia Utama,” she clarified.

As of now, ACT-PLab of ProSTEM has yet to open its services to the public. All of its activities are still based on healthcare-service-based research. However, the latest update is that ProSTEM is reported to have successfully developed stem cells to treat retinitis pigmentosa, a genetic degenerative eye disease.

“Through ACT-PLab, we wish to contribute more in the regenerative treatment field. It is expected to, aside from building autonomy in Indonesia in medical treatment, increase human life expectancy,” Sartika further explained in the press release.

For the record, ACT-PLab has referenced its service based on international standard of cGMP (current Good Manufacturing Practices). With top quality service, ProSTEM wishes for Indonesia to be able to be the host within its own territory, especially in the regenerative therapy field. (ZH)